GlassScriptPhysician profile
Scott J Massa
NPI 1588666986
$2,355.40
in general payments reported to CMS, 2019-2025
18 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $55.73 · 2021: $253 · 2022: $254 · 2023: $182 · 2024: $289 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,054.71 | 2019-2025 | |
| Novo Nordisk INC | $605.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $125.93 | 2019-2022 | |
| Abbvie INC. | $82.30 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $73.90 | 2021-2024 | |
| Lilly USA, LLC | $67.63 | 2019-2025 | Mounjaro |
| Abbott Laboratories | $56.00 | 2024-2025 | Cardiomems, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $40.26 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $39.63 | 2022 | |
| Xeris Pharmaceuticals, INC. | $34.92 | 2022-2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $30.97 | 2019-2023 | Veozah |
| Amgen INC. | $26.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.52 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.33 | 2022 | |
| Medtronic, INC. | $22.49 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $16.93 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $14.41 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $12.77 | 2023 | Belsomra, Steglatro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Massa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.